Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > HAPPY #*%@%&* ANNIVERSARY!
View:
Post by ISAloser247 on Jul 22, 2010 12:02pm

HAPPY #*%@%&* ANNIVERSARY!



It is two years to the day that Hoffman Roche said  AU REVOIR and Robert Foster said

"this represents the first time since 2002 that we can offer a more comprehensive licensing package

including both transplant and qutoimmune indications to a focused and strong global partner"


T- minus 13 days and counting!


POOF!  
Comment by Pincher on Jul 22, 2010 12:43pm
This post has been removed in accordance with Community Policy
Comment by Psycho666 on Jul 22, 2010 1:45pm
Two years ago today - the share price was at .32....The only ones making money from this company are the paid employees.Some things never change...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities